A Phase 1 trial of venetoclax monotherapy showed that myeloma patients with t(11;14)-positive tumors, which tend to express high levels of BCL-2 and low levels of BCL-XL and MCL-1, showed an objective response rate of 40% (54). Here, BCL2 is linked to plasma cell myeloma.